Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 37
Filter
1.
J Infect Dis ; 183(10): 1476-84, 2001 May 15.
Article in English | MEDLINE | ID: mdl-11319683

ABSTRACT

To evaluate the safety and efficacy of 3 regimens of intermittent subcutaneous (sc) interleukin (IL)--2 in a phase 2 study, 61 antiviral drug-experienced human immunodeficiency virus (HIV)--positive patients were randomly assigned to one of the following study arms: antiretroviral therapy (ART) plus IL-2 (12 million IU [MIU] by continuous intravenous infusion, followed by 7.5 MIU twice a day, sc, every 8 weeks); ART plus IL-2 (7.5 MIU twice a day, sc, every 8 weeks); ART plus IL-2 (3 MIU twice a day, sc, every 4 weeks); or ART alone. A significant increase of circulating CD4 cells was observed in IL-2--treated subjects, compared with those given ART alone. Low doses of IL-2 were better tolerated. Despite the incomplete suppression of viral replication, IL-2 with ART did not increase either plasma viremia or cell-associated HIV DNA levels. Low doses of intermittent sc IL-2 induced a stable increase of peripheral CD4 cells that was indistinguishable from those associated with higher, less well-tolerated doses of IL-2.


Subject(s)
Anti-HIV Agents/administration & dosage , HIV Infections/drug therapy , HIV Infections/virology , Interleukin-2/administration & dosage , Adult , Anti-HIV Agents/adverse effects , Anti-HIV Agents/therapeutic use , CD4 Lymphocyte Count , DNA, Viral/analysis , Drug Resistance , Follow-Up Studies , Genotype , HIV Infections/immunology , HIV Protease Inhibitors/therapeutic use , HIV-1/genetics , HIV-1/isolation & purification , Humans , Injections, Subcutaneous , Interleukin-2/adverse effects , Interleukin-2/therapeutic use , Kinetics , Male , Middle Aged , Reverse Transcriptase Inhibitors/therapeutic use , T-Lymphocytes/virology , Viral Load , Viremia/drug therapy , Viremia/immunology , Viremia/virology
3.
Nat Neurosci ; 3(1): 41-6, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10607393

ABSTRACT

Sonic Hedgehog (Shh) is a secreted protein that controls cell fate and mitogenesis in the developing nervous system. Here we show that a constitutively active form of Smoothened (Smo-M2) mimics concentration-dependent actions of Shh in the developing neural tube, including activation of ventral marker genes (HNF3beta, patched, Nkx2.2, netrin-1), suppression of dorsal markers (Pax-3, Gli-3, Ephrin A5) and induction of ventral neurons (dopaminergic, serotonergic) and ventrolateral motor neurons (Islet-1+, Islet-2+, HB9+) and interneurons (Engrailed-1+, CHX10+). Furthermore, Smo-M2's patterning activities were cell autonomous, occurring exclusively in cells expressing Smo-M2. These findings suggest that Smo is a key signaling component in the Hh receptor and that Shh patterns the vertebrate nervous system as a morphogen, rather than through secondary relay signals.


Subject(s)
Body Patterning/physiology , Embryonic Induction , Neural Crest/embryology , Receptors, Cell Surface/physiology , Receptors, G-Protein-Coupled , Signal Transduction/physiology , Trans-Activators , Amino Acid Substitution , Animals , Antigens, Differentiation/metabolism , Body Patterning/genetics , Brain/cytology , Brain/embryology , Brain/metabolism , Chick Embryo , Embryo, Mammalian , Gene Expression Regulation, Developmental , Genes, Reporter , Hedgehog Proteins , Homeobox Protein Nkx-2.2 , Interneurons/cytology , Interneurons/metabolism , Mice , Mice, Transgenic , Motor Neurons/cytology , Motor Neurons/metabolism , Neural Crest/cytology , Neural Crest/metabolism , Proteins/physiology , Receptors, Cell Surface/genetics , Receptors, Cell Surface/metabolism , Signal Transduction/genetics , Smoothened Receptor , Spinal Cord/cytology , Spinal Cord/embryology , Transfection
4.
Exp Cell Res ; 253(1): 25-33, 1999 Nov 25.
Article in English | MEDLINE | ID: mdl-10579908

ABSTRACT

The patterning and morphogenesis of multicellular organisms require a complex interplay of inductive signals which control proliferation, growth arrest, and differentiation of different cell types. A number of such signaling molecules have been identified in vertebrates and invertebrates. The molecular dissection of these pathways demonstrated that in vertebrates, mutations or abnormals function of these signaling pathways were often associated with developmental disorders and cancer formation. The Hedgehog (Hh) family of secreted proteins provides a perfect example of such signaling proteins. In the following review, we will not discuss in detail the role of Hh as a morphogen, but rather focus on its signal transduction pathway and its role in various human disorders.


Subject(s)
Drosophila Proteins , Insect Proteins/metabolism , Proteins/metabolism , Receptors, Cell Surface/metabolism , Receptors, G-Protein-Coupled , Signal Transduction/physiology , Trans-Activators , Chromosome Aberrations , Chromosome Disorders , Embryonic Induction , Hedgehog Proteins , Humans , Membrane Proteins/metabolism , Models, Molecular , Patched Receptors , Smoothened Receptor , Transcription Factors/metabolism
5.
J Cell Sci ; 112 ( Pt 23): 4437-48, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10564661

ABSTRACT

Drosophila Suppressor of fused (Su(fu)) encodes a novel 468-amino-acid cytoplasmic protein which, by genetic analysis, functions as a negative regulator of the Hedgehog segment polarity pathway. Here we describe the primary structure, tissue distribution, biochemical and functional analyses of a human Su(fu) (hSu(fu)). Two alternatively spliced isoforms of hSu(fu) were identified, predicting proteins of 433 and 484 amino acids, with a calculated molecular mass of 48 and 54 kDa, respectively. The two proteins differ only by the inclusion or exclusion of a 52-amino-acid extension at the carboxy terminus. Both isoforms were expressed in multiple embryonic and adult tissues, and exhibited a developmental profile consistent with a role in Hedgehog signaling. The hSu(fu) contains a high-scoring PEST-domain, and exhibits an overall 37% sequence identity (63% similarity) with the Drosophila protein and 97% sequence identity with the mouse Su(fu). The hSu(fu) locus mapped to chromosome 10q24-q25, a region which is deleted in glioblastomas, prostate cancer, malignant melanoma and endometrial cancer. HSu(fu) was found to repress activity of the zinc-finger transcription factor Gli, which mediates Hedgehog signaling in vertebrates, and to physically interact with Gli, Gli2 and Gli3 as well as with Slimb, an F-box containing protein which, in the fly, suppresses the Hedgehog response, in part by stimulating the degradation of the fly Gli homologue. Coexpression of Slimb with Su(fu) potentiated the Su(fu)-mediated repression of Gli. Taken together, our data provide biochemical and functional evidence for the hypothesis that Su(fu) is a key negative regulator in the vertebrate Hedgehog signaling pathway. The data further suggest that Su(fu) can act by binding to Gli and inhibiting Gli-mediated transactivation as well as by serving as an adaptor protein, which links Gli to the Slimb-dependent proteasomal degradation pathway.


Subject(s)
Chromosomes, Human, Pair 10 , Drosophila Proteins , Gene Expression Regulation, Developmental , Oncogene Proteins/metabolism , Repressor Proteins/genetics , Repressor Proteins/metabolism , Transcription Factors/metabolism , Adult , Alternative Splicing , Amino Acid Sequence , Animals , Cell Line , Chromosome Mapping , Cloning, Molecular , Drosophila , Female , Fetus , Gene Expression Regulation , Humans , Luciferases/genetics , Male , Mice , Molecular Sequence Data , Polymerase Chain Reaction , Protein Isoforms/genetics , Protein Isoforms/metabolism , Recombinant Fusion Proteins/biosynthesis , Repressor Proteins/chemistry , Sequence Alignment , Sequence Homology, Amino Acid , Trans-Activators , Zinc Finger Protein GLI1 , Zinc Fingers
6.
Eur J Immunol ; 29(11): 3654-62, 1999 11.
Article in English | MEDLINE | ID: mdl-10556821

ABSTRACT

The U937-derived chronically HIV-infected U1 cell line and uninfected U937 cell clones were efficiently lysed by both unstimulated (NK) and IL-2-stimulated (lymphokine-activated killer; LAK) peripheral blood mononuclear cells (PBMC) of healthy HIV-seronegative donors. Pretreatment of target cells with IFN-gamma down-modulated killing of both U1 cells and two U937 cell clones, and up-regulated MHC class I expression. In contrast, TNF-alpha enhanced the sensitivity of infected U1 cells, but not of U937 cell clones to NK / LAK cell lysis. Co-cultivation of IL-2-stimulated PBMC with U1 cells triggered expression and replication of HIV by cell-cell contact, and this effect was inhibited by anti-TNF-alpha antibodies (Ab); virus production was partially inhibited by zidovudine. Of interest, anti-TNF-alpha Ab protected U1 cells from LAK cell activity. Thus, TNF-alpha can induce HIV expression from chronically infected U1 cells, but also plays an important role in sensitizing these cells to lysis.


Subject(s)
HIV-1/immunology , Killer Cells, Lymphokine-Activated/immunology , Killer Cells, Natural/immunology , Tumor Necrosis Factor-alpha/immunology , Coculture Techniques , Cytotoxicity, Immunologic , HIV Reverse Transcriptase/biosynthesis , HIV-1/growth & development , Humans , Interferon-gamma/immunology , Interleukin-2/immunology , Interleukin-2/pharmacology , Leukocytes, Mononuclear/immunology , Recombinant Proteins/immunology , Recombinant Proteins/pharmacology , U937 Cells
7.
J Cell Sci ; 112 Pt 18: 3103-14, 1999 Sep.
Article in English | MEDLINE | ID: mdl-10462526

ABSTRACT

Schizosaccharomyces pombe cdc16p is required to limit the cell to forming a single division septum per cell cycle; the heat-sensitive loss-of-function mutant cdc16-116 completes mitosis, and then undergoes multiple rounds of septum formation without cell cleavage. cdc16p is a homologue of Saccharomyces cerevisiae BUB2p, and has also been implicated in the spindle assembly checkpoint function in S. pombe. To identify other proteins involved in regulating septum formation, we have screened for multicopy suppressors of the cdc16-116 mutation. In this paper, we describe one of these suppressors, zfs1. The null allele (zfs1-D1) is viable. However, at low temperatures it divides at a reduced size, while at higher temperatures, it partially suppresses heat sensitive mutants in genes signalling the onset of septum formation. Zfs1-D1 cells show an increased rate of chromosome loss during exponential growth. Moreover, if assembly of the spindle is prevented, zfs1-D1 cells do not arrest normally, but the activity of cdc2p kinase decays, and cells form a division septum without completing a normal mitosis. We conclude that zfs1 function is required to prevent septum formation and exit from mitosis if the mitotic spindle is not assembled. The suppression of cdc16-116 by zfs1 is independent of dma1 function and the spindle assembly checkpoint genes mad2 and mph1. The genetic interactions of zfs1 with genes regulating septum formation suggest that it may be a modulator of the signal transduction network controlling the onset of septum formation and exit from mitosis.


Subject(s)
Carrier Proteins , Fungal Proteins/genetics , Genes, Fungal , Nuclear Proteins/genetics , Schizosaccharomyces pombe Proteins , Schizosaccharomyces/cytology , Schizosaccharomyces/genetics , Actins/metabolism , Calcium-Binding Proteins/genetics , Cell Cycle Proteins/genetics , Cell Division/genetics , Gene Deletion , Gene Expression , Genes, Suppressor , Mad2 Proteins , Mitosis/genetics , Mutation , Saccharomyces cerevisiae Proteins , Schizosaccharomyces/metabolism , Signal Transduction
8.
Curr Biol ; 9(2): 76-84, 1999 Jan 28.
Article in English | MEDLINE | ID: mdl-10021362

ABSTRACT

BACKGROUND: The Hedgehog (Hh) family of secreted proteins is involved in a number of developmental processes as well as in cancer. Genetic and biochemical data suggest that the Sonic hedgehog (Shh) receptor is composed of at least two proteins: the tumor suppressor protein Patched (Ptc) and the seven-transmembrane protein Smoothened (Smo). RESULTS: Using a biochemical assay for activation of the transcription factor Gli, a downstream component of the Hh pathway, we show here that Smo functions as the signaling component of the Shh receptor, and that this activity can be blocked by Ptc. The inhibition of Smo by Ptc can be relieved by the addition of Shh. Furthermore, oncogenic forms of Smo are insensitive to Ptc repression in this assay. Mapping of the Smo domains required for binding to Ptc and for signaling revealed that the Smo-Ptc interaction involves mainly the amino terminus of Smo, and that the third intracellular loop and the seventh transmembrane domain are required for signaling. CONCLUSIONS: These data demonstrate that Smo is the signaling component of a multicomponent Hh receptor complex and that Ptc is a ligand-regulated inhibitor of Smo. Different domains of Smo are involved in Ptc binding and activation of a Gli reporter construct. The latter requires the third intracellular loop and the seventh transmembrane domain of Smo, regions often involved in coupling to G proteins. No changes in the levels of cyclic AMP or calcium associated with such pathways could be detected following receptor activation, however.


Subject(s)
Drosophila Proteins , Membrane Proteins/metabolism , Oncogene Proteins/metabolism , Receptors, G-Protein-Coupled , Signal Transduction , Transcription Factors/metabolism , Amino Acid Sequence , Animals , Binding Sites , COS Cells , Insect Proteins/genetics , Insect Proteins/metabolism , Intracellular Signaling Peptides and Proteins , Membrane Proteins/genetics , Mice , Mice, Inbred C3H , Molecular Sequence Data , Patched Receptors , Patched-1 Receptor , Receptors, Cell Surface/chemistry , Receptors, Cell Surface/metabolism , Recombinant Proteins/metabolism , Repressor Proteins/metabolism , Sequence Homology, Amino Acid , Smoothened Receptor , Trans-Activators , Zinc Finger Protein GLI1
9.
Stem Cells ; 16(1): 1-6, 1998.
Article in English | MEDLINE | ID: mdl-9474742

ABSTRACT

Thrombopoietin (TPO) is the primary regulatory of megakaryocyte (Meg) and platelet production. Its receptor, c-mpl, is a member of the cytokine receptor superfamily. Major insight into the physiological role of this receptor/ligand pair came from the study of mice carrying disrupted alleles of these two genes. Both TPO and c-mpl knockout mice are viable, but have a 90% reduction in platelet counts. Their thrombocytopenia is caused by a reduction in progenitor cell numbers and a decrease in Meg ploidy. However, the Megs and platelets produced in the absence of TPO or c-mpl appear morphologically and functionally normal indicating that, in vivo, the main role of TPO is to control their numbers, rather than their maturation. In addition to its effect on the Meg lineage, TPO also affects hematopoietic stem cells as measured by a reduction of the repopulating capacity of bone marrow cells from c-mpl-deficient mice. Finally, analysis of these gene targeted mice provided substantial evidence to a model where the circulating TPO level is directly regulated by the platelet mass through binding to c-mpl receptors present at the platelet surface. This elegant feedback mechanism allows a tight regulation of the amount of TPO available to stimulate megakaryocytopoiesis.


Subject(s)
Hematopoiesis/physiology , Neoplasm Proteins , Proto-Oncogene Proteins/physiology , Receptors, Cytokine , Thrombocytopenia/blood , Thrombopoietin/physiology , Animals , Mice , Mice, Knockout , Receptors, Thrombopoietin
10.
Nature ; 391(6662): 90-2, 1998 Jan 01.
Article in English | MEDLINE | ID: mdl-9422511

ABSTRACT

Basal-cell carcinomas (BCCs) are the commonest human cancer. Insight into their genesis came from identification of mutations in the PATCHED gene (PTCH) in patients with the basal-cell nevus syndrome, a hereditary disease characterized by multiple BCCs and by developmental abnormalities. The binding of Sonic hedgehog (SHH) to its receptor, PTCH, is thought to prevent normal inhibition by PTCH of Smoothened (SMO), a seven-span transmembrane protein. According to this model, the inhibition of SMO signalling is relieved following mutational inactivation of PTCH in basal-cell nevus syndrome. We report here the identification of activating somatic missense mutations in the SMO gene itself in sporadic BCCs from three patients. Mutant SMO, unlike wild type, can cooperate with adenovirus E1A to transform rat embryonic fibroblast cells in culture. Furthermore, skin abnormalities similar to BCCs developed in transgenic murine skin overexpressing mutant SMO. These findings support the role of SMO as a signalling component of the SHH-receptor complex and provide direct evidence that mutated SMO can function as an oncogene in BCCs.


Subject(s)
Carcinoma, Basal Cell/genetics , Mutation , Receptors, Cell Surface/genetics , Receptors, G-Protein-Coupled , Skin Neoplasms/genetics , Trans-Activators , Adenovirus E1A Proteins/genetics , Adenovirus E1A Proteins/physiology , Animals , Cell Line , Chromosome Mapping , Chromosomes, Human, Pair 7 , Hedgehog Proteins , Humans , Intracellular Signaling Peptides and Proteins , Membrane Proteins/genetics , Membrane Proteins/metabolism , Mice , Mice, Transgenic , Oncogenes , Patched Receptors , Patched-1 Receptor , Polymerase Chain Reaction , Protein Conformation , Proteins/metabolism , Rats , Receptors, Cell Surface/chemistry , Receptors, Cell Surface/physiology , Signal Transduction , Smoothened Receptor , Transfection
11.
J Biol Regul Homeost Agents ; 11(1-2): 74-8, 1997.
Article in English | MEDLINE | ID: mdl-9418168

ABSTRACT

Since the clinical earliest descriptions of patients with acquired immune deficiency syndrome (AIDS) it has been very clear that a profound state of immunologic dysfunction was the underlying cause of the emergence of life-threatening opportunistic infections and tumors. In addition to the progressive loss of CD4 "helper" T lymphocytes, a profound defect in interleukin-2 (IL-2) production was recognized as a major pathogenic component of the new disease. For these reasons, attempts to administer IL-2 to individuals infected with the human immunodeficiency virus (HIV), the causative agent of AIDS, have been made since the mid eighties, however with little success. On the other hand, the propensity of HIV to replicate in activated lymphocytes and macrophages, under the influence of the cytokine network, has represented, and in part still does, a major hurdle for the rationale of administering IL-2 or other cytokines to HIV-infected individuals. Major steps forward towards an understanding of the role of multiple components of the immune system, coupled with a potentially successful protocol of IL-2 administration in vivo, resulting in the stable uprising of circulating CD4+ T cells, shed an optimistic light on the possibility to achieve a substantial immune reconstitution in HIV-infected individuals, thus preventing the onset of AIDS.


Subject(s)
HIV Infections/immunology , HIV-1 , Immunity, Cellular/drug effects , Interleukin-2/therapeutic use , Adjuvants, Immunologic/therapeutic use , HIV Infections/drug therapy , Humans , Interleukin-2/immunology
12.
EMBO J ; 15(23): 6605-16, 1996 Dec 02.
Article in English | MEDLINE | ID: mdl-8978687

ABSTRACT

Premature initiation of cytokinesis can lead to loss of chromosomes, and 'cutting' of the nucleus. Therefore, the proper spatial and temporal co-ordination of mitosis and cytokinesis is essential for maintaining the integrity of the genome. The fission yeast cdc16 gene is implicated both in the spindle assembly checkpoint and control of septum formation. To identify other proteins involved in these controls, we have isolated multicopy suppressors of the cdc16-116 mutation, and the characterization of one of these, dma1 (defective in mitotic arrest), is presented here. dma1 is not an essential gene, but in a dma1 null background (dma1-D1) the function of the spindle assembly checkpoint is compromised. If assembly of the spindle is prevented, dma1-D1 cells do not arrest, the activity of cdc2 kinase decays and cells form a division septum without completing a normal mitosis. dma1-D1 cells also show an increased rate of chromosome loss during exponential growth. Upon ectopic expression from an inducible promoter, dma1p delays progress through mitosis and inhibits septum formation, giving rise to elongated, multinucleate cells. We propose that dma1 is a component of the spindle assembly checkpoint, required to prevent septum formation and premature exit from mitosis if spindle function is impaired.


Subject(s)
Cell Cycle Proteins/metabolism , Cell Cycle , Genes, Fungal , Schizosaccharomyces pombe Proteins , Schizosaccharomyces/cytology , Schizosaccharomyces/genetics , Spindle Apparatus , Amino Acid Sequence , Cell Cycle Proteins/chemistry , Cell Cycle Proteins/genetics , Chromosome Deletion , Chromosomes, Fungal , Cloning, Molecular , Fungal Proteins/metabolism , Gene Deletion , Mitosis , Molecular Sequence Data , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Saccharomyces cerevisiae , Sequence Homology, Amino Acid
14.
J Chromatogr ; 615(1): 59-66, 1993 May 19.
Article in English | MEDLINE | ID: mdl-8340463

ABSTRACT

Glucosyl-galactosyl-hydroxylysine (GGHYL) and galactosyl-hydroxylysine (GHYL) are constituents of collagen protein. The ratio of the two hydroxylysine glycosides varies with the collagen type and, moreover, for a given collagen type, it also varies according to the connective tissue. For example, in type I collagen (the most abundant in the body), the GGHYL/GHYL ratio tends to be greater in soft connective tissues and lower in bone. The hydroxylysine glycosides are not recycled during collagen turnover and are excreted in the urine. Therefore, the urinary GGHYL/GHYL ratio, which reflects the proportion of the two metabolites in the various collagens, may indicate the type of connective tissue affected by pathological turnover, and may thus be a promising marker of bone metabolism. In this paper a method is described for the measurement of urinary hydroxylysine glycosides by reversed-phase liquid chromatography after purification of the sample by solid-phase extraction. The method presented is analytically reliable and suitable for routine use in a clinical laboratory.


Subject(s)
Bone and Bones/metabolism , Collagen/metabolism , Hydroxylysine/analogs & derivatives , Adult , Biomarkers , Chromatography, High Pressure Liquid , Female , Humans , Hydroxylysine/urine , Indicators and Reagents , Osteoporosis/metabolism , Reference Standards , Spectrophotometry, Ultraviolet
16.
Clin Chem ; 37(2): 273-6, 1991 Feb.
Article in English | MEDLINE | ID: mdl-1993338

ABSTRACT

Measurement of human growth hormone (hGH; somatotropin) concentrations in serum after provocative tests is crucial for diagnosing deficiencies in production of this hormone. Serum hGH can be measured by various immunoassays, isotopic and nonisotopic, with monoclonal or polyclonal antibodies: a cutoff value of 10 micrograms/L after provocative testing is usually used to distinguish normal from hGH-deficient children. Previous studies demonstrated discrepancies in hGH measurement by different radioisotopic immunoassays. Here we evaluated the responses of six different commercial assays, radioisotopic and nonisotopic, with monoclonal or polyclonal antibodies in a series of 16 provocative tests (stimulation with clonidine) in short children. A wide range of discrepant values was obtained with the different kits. A cutoff of 10 micrograms/L produced discordance of diagnosis among assays for two children, whereas complete agreement was reached for a cutoff value of 7 micrograms/L. Parallelism tests performed with hGH international standard, pure recombinant hGH, and a serum with high hGH content suggest that heterogeneity of the antibodies used by the manufacturers, even among monoclonal antibodies, is the main source of discordant results. Cutoff values and reference values must be established separately for each method proposed for routine use.


Subject(s)
Growth Hormone/blood , Adolescent , Antibodies, Monoclonal , Child , Diagnosis, Differential , Female , Growth Hormone/deficiency , Humans , Immunoradiometric Assay , Male , Radioimmunoassay , Reagent Kits, Diagnostic , Turner Syndrome/blood , Turner Syndrome/diagnosis
17.
Article in English | MEDLINE | ID: mdl-1780692

ABSTRACT

The concentrations of tumor-associated trypsin inhibitor (TATI) in the seminal plasma of infertile males was studied. The TATI levels in seminal plasma were not correlated with either sperm count or ejaculate volume. High levels were observed in some men with unexplained infertility and high or normal sperm counts, whereas normal levels were observed in males with antisperm antibodies. The concentrations in seminal plasma were stable in the same subjects. These results suggest that TATI may be an important marker of reproductive pathology in men.


Subject(s)
Biomarkers, Tumor/analysis , Infertility, Male/diagnosis , Trypsin Inhibitor, Kazal Pancreatic/analysis , Adult , Antibodies/analysis , Humans , Infertility, Male/metabolism , Male , Semen/chemistry , Spermatozoa/immunology
18.
Article in English | MEDLINE | ID: mdl-1780693

ABSTRACT

A new tumor marker, tumor-associated trypsin inhibitor (TATI), was studied in 5 patients who received successful kidney or pancreas grafts and in 30 subjects with antibodies against human immunodeficiency virus. Serum TATI concentrations were very high during the four first days after transplantation. Thereafter the serum levels decreased when the peptide was eliminated through the kidney. Consequently, the urine values were very high. The TATI concentrations of HIV positive subjects were compared with serum levels of HIV antigen and antibody, by Western blotting and determination of peripheral T-lymphocyte subpopulations. The occurrence of high concentrations of TATI in some HIV positive subjects and especially in AIDS patients, suggests that TATI could be useful in exploring physiopathological aspects of severe immunodeficiencies even if TATI levels were not correlated with the commonly used markers of the immune system status. The increased levels of TATI in immunological disorders suggests its possible use in assessing the immune response against cancer.


Subject(s)
AIDS-Related Complex/metabolism , Acquired Immunodeficiency Syndrome/metabolism , Biomarkers, Tumor/analysis , Immunosuppressive Agents/therapeutic use , Transplantation Immunology , Trypsin Inhibitor, Kazal Pancreatic/analysis , Adolescent , Adult , Aged , Humans , Kidney Transplantation/immunology , Middle Aged , Pancreas Transplantation/immunology
20.
J Biolumin Chemilumin ; 5(3): 193-5, 1990.
Article in English | MEDLINE | ID: mdl-2220417

ABSTRACT

We evaluated the Amerlite system (Amersham, Bucks, UK) for hCG and FT4. The within-run imprecision (CV%) for hCG was 4.05 at 19.6 U/l (n = 10), 6.28 at 43.45 U/l (n = 10) and 4.62 at 298.57 U/l (n = 10). The between-run imprecision (five replicates for ten days) was 4.8%, 15% and 11%, respectively. The system was linear up to 200 U/l. A good correlation between Amerlite hCG and an IRMA assay (Becton Dickinson, r = 0.91), Delfia (Pharmacia, r = 0.91) and an automated ELISA assay on ES 600 (Boehringer, r = 0.92) was observed on 70 samples. Within-run imprecision for FT4 was 3.8% at 0.7 ng/dl (n = 10), 3.3% at 1 ng/dl (n = 10) and 4.32% at 5.15 ng/dl (n = 10), and between-run was 5.95%, 4.4% and 8.2%, respectively. The comparison with a commercial direct RIA (Becton Dickinson) showed good correlation (r = 0.90, n = 100 samples). The diagnostic value of the association of thyrotropin and FT4, in comparison with the traditional thyroid tests (T3, T4, thyrotropin, FT4, FT3) has been assessed in various thyroid diseases.


Subject(s)
Chorionic Gonadotropin/blood , Luminescent Measurements , Thyroxine/blood , Evaluation Studies as Topic , Humans , Immunoassay/methods , Quality Control
SELECTION OF CITATIONS
SEARCH DETAIL